At the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, the Eye Care Network caught up with Jogin ...

A recent analysis reveals that ellipsoidal zone-retinal pigment epithelial thickness predicts future visual loss in ...

Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in ...

Boehringer Ingelheim has started a proof-of-concept trial of a drug that could offer the first oral treatment for geographic ...

RESEARCH TRIANGLE PARK, N.C. and PALO ALTO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a ...

Cognition Therapeutics has announced positive topline outcomes from the Phase II MAGNIFY trial of zervimesine in adult ...

The study aims to identify the optimal dose of BI 1584862 and observe its impact on improving GA patients' eyes.

Hamby and Lizama, shows zervimesine may protect retinal cells from the onslaught ... concept clinical trial in 100 people with geographic atrophy secondary to dry AMD, treatment with zervimesine ...

KRIYA-825 is an adeno-associated virus (AAV)-based gene therapy that expresses a complement CR2-CR1 fusion protein for the treatment of Geographic Atrophy, a prevalent degenerative retinal disease ...

Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a potential first-in-class treatment for ...